The results from IPS scoring analyses revealed that GC patients with lower levels of CLEC11A were more likely to benefit from immunotherapy in two specific groups (CTLA4-/PD-1- and CTLA4+/PD-1-). The gene discussed is CTLA4; the disease is gastric cancer.